** Shares of U.S. drugmaker Eli Lilly LLY.N rise 2.11% to $900.01 premarket
** The company says it has begun selling vials of higher dosages of its popular weight-loss drug Zepbound, which is typically sold in auto-injector pens, in the U.S.
** The vials are priced at a $150 discount to the cost of the injector pen version
** Says patients can purchase 7.5 mg and 10mg vials of Zepbound for $499 a month on from its B2C LillyDirect website
** Last August, co launched two lower dose vials of Zepbound to help increase availability
** Says it had reduced prices for a month's supply of lower dosage vials by around $50
** LLY rose 14.5% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。